Background:COVID-19 remains a common threat to public health.In this study,we evaluated the antiviral effects and safety of Darunavir/Cobicisitat(DRV/c)in patients with confirmed COVID-19.Patients and Methods:We studi...Background:COVID-19 remains a common threat to public health.In this study,we evaluated the antiviral effects and safety of Darunavir/Cobicisitat(DRV/c)in patients with confirmed COVID-19.Patients and Methods:We studied 66 patients with COVID-19 infection who were admitted to Zhongnan Hospital of Wuhan University between February 3 and March 11,2020.The patients were divided into the DRV/c and the control groups.The primary endpoint was the time of SARS-CoV-2 nucleic acid conversion detected in respiratory specimens.Results:Subjects with confirmed SARS-CoV-2 infection(n=66)were enrolled in this study;32 subjects were enrolled in the DRV/c group and 34 in the control group.The mean time to nucleic acid conversion(NAC)was shorter in the DRV/c group.The cumulative nucleic acid conversion rate(CNACR)in the DRV/c group was higher during the first two weeks,but the difference was not statistically significant.The proportion of fever during hospitalization in the DRV/c group was significantly lower than in the control group(P-value=0.01).It was found that,in the DRV/c group,the NAC of patients with a duration from symptom onset to admission within three days was significantly shorter(7.9±6.7 days)than in patients with a duration from symptom onset to admission above three days(15.9±7.1 days)(P=0.01).Conclusion:Although the combination of DRV/c and routine treatment for patients with non-severe COVID-19 can significantly reduce the proportion of fever after admission,no significant differences were observed between the DRV/c group and the conventional therapy group,including the overall time to NAC,safety,and tolerability.展开更多
基金supported by the Key Project for Anti-2019 Novel Coronavirus Pneumonia from the National Key Research and Development Program of China(Grant No.2020YFC0845500)the Fundamental Research Funds for the Central Universities(Grant No.2042020kf1018).
文摘Background:COVID-19 remains a common threat to public health.In this study,we evaluated the antiviral effects and safety of Darunavir/Cobicisitat(DRV/c)in patients with confirmed COVID-19.Patients and Methods:We studied 66 patients with COVID-19 infection who were admitted to Zhongnan Hospital of Wuhan University between February 3 and March 11,2020.The patients were divided into the DRV/c and the control groups.The primary endpoint was the time of SARS-CoV-2 nucleic acid conversion detected in respiratory specimens.Results:Subjects with confirmed SARS-CoV-2 infection(n=66)were enrolled in this study;32 subjects were enrolled in the DRV/c group and 34 in the control group.The mean time to nucleic acid conversion(NAC)was shorter in the DRV/c group.The cumulative nucleic acid conversion rate(CNACR)in the DRV/c group was higher during the first two weeks,but the difference was not statistically significant.The proportion of fever during hospitalization in the DRV/c group was significantly lower than in the control group(P-value=0.01).It was found that,in the DRV/c group,the NAC of patients with a duration from symptom onset to admission within three days was significantly shorter(7.9±6.7 days)than in patients with a duration from symptom onset to admission above three days(15.9±7.1 days)(P=0.01).Conclusion:Although the combination of DRV/c and routine treatment for patients with non-severe COVID-19 can significantly reduce the proportion of fever after admission,no significant differences were observed between the DRV/c group and the conventional therapy group,including the overall time to NAC,safety,and tolerability.
